ADME in Neonates and Infants: Therapeutics, Toxicity, and Development of New Drugs
Tuesday April 07, 2020
2:00 pm
-
3:30 pm
Eastern Time (ET)
Room 16 B
DDD
DMDD
TOX
Chair :
Pieter Annaert
University of Leuven
Xiao-bo Zhong
University of Connecticut
Patients at ages of neonate and infant are at developmental ages facing special challenges on drug therapy and toxicity. Most prescription drugs are used as off label for neonates and infants. They have the highest medical errors and adverse drug action rates. There is a specific requirement for inclusion of neonates and infants as a study population for therapeutic efficacy, toxicity, and development of new drugs. Several knowledge gaps exist, making too difficult to study neonates and infants. The aim of the symposium is to bring several experts in the field to discuss studies of ADME at these specific ages.
Speakers
Connie Chen
- The Health and Environmental Sciences Institute
ADME Studies in Nonclinical Species to Support Efficacy and Safety of Drug Therapy in Neonates and Infants
Pieter Annaert
- University of Leuven
Ontogeny of ADME Processes during Postnatal Development in Man and Preclinical Species: A Focus on Liver
Xiao-bo Zhong
- University of Connecticut
Short and Long-term Alterations of ADME for Drug Efficacy and Toxicity by Drug Treatment at Neonatal and Infant Ages in Preclinical Species
Jed Lampe
- University of Colorado
CYP3A7 Drug-hormone Interactions in the Neonate: Adrenal Insufficiency and Low Birthweight in the
HIV Infected Neonate caused by Inhibition of CYP3A7 DHEA-S Oxidation by Ritonavir